key: cord-0426433-ijjnswy3
authors: Bottomley, M. J.; Harden, P. N.; Wood, K. J.; Hester, J.; Issa, F.
title: Dampened inflammatory signalling and myeloid-derived suppressor-like cell accumulation reduces circulating monocytic HLA-DR density and associates with malignancy risk in long-term renal transplant recipients
date: 2022-03-23
journal: nan
DOI: 10.1101/2022.03.23.22272699
sha: c1a7bd27a56ab24c6a3f762e1a028ff4b2f60e7a
doc_id: 426433
cord_uid: ijjnswy3

Background: Malignancy is a major cause of morbidity and mortality in transplant recipients. Identification of those at highest risk could facilitate pre-emptive intervention such as reduction of immunosuppression. Reduced circulating monocytic HLA-DR density is a marker of immune depression in the general population and associates with poorer outcome in critical illness. It has recently been used as a safety marker in adoptive cell therapy trials in renal transplantation. Despite its potential as a marker of dampened immune responses, factors that impact upon monocytic HLA-DR density and the long-term clinical sequelae of this have not been assessed in transplant recipients. Methods: A cohort study of stable long-term renal transplant recipients was undertaken. Serial circulating monocytic HLA-DR density and other leucocyte populations were quantified by flow cytometry. Gene expression of monocytes was performed using the Nanostring nCounter platform, and 13-plex cytokine bead array used to quantify serum concentrations. The primary outcome was malignancy development during one-year follow-up. Risk of malignancy was calculated by univariate and multivariate proportionate hazards modelling with and without adjustment for competing risks. Results: Monocytic HLA-DR density was stable in long-term renal transplant recipients (n=135) and similar to non-immunosuppressed controls (n=29), though was suppressed in recipients receiving prednisolone. Decreased mHLA-DRd was associated with accumulation of CD14+CD11b+CD33+HLA-DRlo monocytic myeloid-derived suppressor-like cells. Pathway analysis revealed downregulation of pathways relating to cytokine and chemokine signalling in monocytes with low HLA-DR density; however serum concentrations of major cytokines did not differ between these groups. There was an independent increase in malignancy risk during follow-up with decreased HLA-DR density. Conclusions: Dampened chemokine and cytokine signalling drives a stable reduction in monocytic HLA-DR density in long-term transplant recipients and associates with subsequent malignancy risk. This may function as a novel marker of excess immunosuppression. Further study is needed to understand the mechanism behind this association.

Inc) as previously published (28). Monocyte populations were stained using thawed PBMC 137 according to gating proposed by Marimuthu et al (29) to minimize non-monocyte contamination. 138

Leukocyte counts from simultaneous routine haematology laboratory testing were used to calculate 139 absolute cell counts. Total RNA was extracted from enriched monocytes by column-based isolation (RNEasy Micro Kit, 148 Qiagen, Manchester, United Kingdom). 25ng RNA was hybridized to fluorescent barcode-labeled 149 probes from the nCounter Myeloid Innate Immunity V2 Panel (Reference:  150 XT_PGX_HuV2_Myeloid_CSO, Nanostring Technologies, Seattle, United States) prior to analysis 151 on the nCounter SPRINT platform (Nanostring, Technologies, Seattle, United States). 152

Count data was initially analyzed by ROSALIND (https://rosalind.bio/), with a HyperScale 153 architecture developed by ROSALIND, Inc. (San Diego, CA). Normalization, fold changes and p-154 values were calculated using criteria provided by Nanostring, following the nCounter Advanced 155

Analysis protocol of dividing counts within a lane by the geometric mean of the normalizer probes 156 from the same lane. Housekeeping probes to be used for normalization were selected based on the 157 geNorm algorithm as implemented in the NormqPCR R library (30). Fold changes and pValues are 158 calculated using the fast method as described in the nCounter® Advanced Analysis 2.0 User Manual. 159 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 23, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 P-value adjustment is performed using the Benjamini-Hochberg method of estimating false discovery 160 rates (FDR). Downstream analysis was performed using R 4.1.1 and the ClusterProfiler 4.0.5, fgsea 161 1.18.0 and gplots 3.1.1 packages. 162

Cytokines in thawed serum collected at trough immunosuppression and in parallel with collection of 164 blood for leucocyte profile were quantified by bead-based immunoassay in a representative subset of 165 RTR (n=40), using the 'LegendPLEX Human Essential Immune Response Panel' according to 166 manufacturer's instructions. This panel simultaneously quantifies 13 cytokines essential for immune 167 response: IL-4, IL-2, CXCL10 (IP-10), IL-1β, TNF-α, CCL2 (MCP-1), IL-17A, IL-6, IL-10, , and Free Active TGF-β1. Results below the limit of detection were 169 accounted for in two ways; firstly analysis was performed with an imputed value 0.1pg/mL below the 170 limit of detection. Analysis was then repeated with exclusion of these samples (the second approach 171 did not change the significance of results and thus is not reported). 172

The primary clinical outcome of the study was time from enrolment to first diagnosis of malignancy 174 during follow-up. Diagnoses of cutaneous malignancy were made histologically by trained 175 dermatopathologists: where diagnostic uncertainty was present, the pathologist's decision was 176 considered final. If the histologist was unable to provide a favoured diagnosis, a non-diagnosis of 177 SCC was presumed. SCC arising within scar tissue or clinically described as recurrence was 178 excluded. Patients were censored at time of date of last follow-up, date of death/graft loss or 365 179 days, whichever occurred first. 180

Analyses were performed on Graphpad Prism for Windows 9 (Graphpad Software Inc., San Diego, 181 CA), IBM SPSS 27 and R 4.1.1. Continuous variables are shown as mean±standard deviation (SD) 182 unless specified otherwise., Hazard and odds ratios are reported as ratio (95% confidence interval). 183 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 23, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Categorical variables are reported as number (percentage of group). For continuous variables, 184 comparison between groups was performed using non-paired two-tailed t-test (two groups) or 185 analysis of variance with post-hoc testing when initial testing was significant (multiple groups) 186 unless specified otherwise. Correlations were tested using Spearman's test, which is more appropriate 187 for non-parametric data. 188

Change in mHLA-DRd over time and with malignancy development during follow-up was assessed 189 by mixed-effects modelling. Receiver-operator characteristic (ROC) curves were generated using the 190 pROC Figure 1 ). 203

Only those with mHLA-DRd quantification were included in subsequent analyses. All non-204 immunosuppressed controls (n=29) had HLA-DR binding density assessed. 205

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 23, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 The demographics of the cohort are summarised in Table 1 published for healthy controls, without difference between sex (>15000 antibodies (Ab)/cell, Figure  216 2) (25). Two participants demonstrated mHLA-DRd within the previously defined immunodepressed 217 range (25) (8000-15000 Ab/cell) and none within the immunoparesis range (<8000 Ab/cell). Mean 218 mHLA-DRd was reduced by nearly 20% in the transplant recipients compared to the non-219 immunosuppressed control population (40226±2503 vs 32570±1084 Ab/cell, p=0.004). 220

We next asked what factors at recruitment might influence mHLA-DRd in otherwise stable transplant 221 recipients ( Figure 3 and Table 2 ). On univariate analysis after removal of outliers (n=3), no major 222 demographic factor was associated with mHLA-DRd. Notably, there was a significant reduction in 223 mHLA-DRd in RTR receiving corticosteroid therapy and a stepwise and significant decrease in 224 mHLA-DRd by number of agents taken, though a significant difference was only seen between RTR 225 receiving monotherapy and triple therapy on post-hoc testing. RTR on dual and triple therapy 226 exhibited significantly lower mHLA-DRd compared to non-immunosuppressed controls. 227

Due to the potential for overlapping and conflicting influence of immunomodulatory agents, we 228 undertook a multivariate regression analysis incorporating induction therapy, use of sirolimus or 229 prednisolone at recruitment and number of immunosuppressive agents at recruitment as covariates. 230 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 23, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Age at recruitment was also included as a pre-specified variable, as immune ageing can lead to 231 chronic innate immune activation and has recently been found to associate with alterations in 232 monocyte function in renal transplant recipients. 31,32 233 This model demonstrated that prednisolone use at recruitment independently predicted a reduction in 234 mHLA-DRd (Beta = -0.30, t(126) = -2.86 , p=0.005) with a trend towards the opposite in RTR taking 235 sirolimus at recruitment (Beta = 0.16, t(126) = 1.89, p=0.06). It should be noted that the magnitudes 236 of these effects were relatively small. Induction agent and number of immunosuppressive agents 237 taken did not remain predictive after adjustment (Supplementary Table 2) . 238

There was no clear dose-response relationship with regard to corticosteroid therapy -whilst all RTR 239 taking prednisolone demonstrated reduced mHLA-DRd compared to those not taking it, this did not 240 appear to correlate with weight-adjusted dose taken (Supplementary Figure 2) . 241

We next assessed the medium-term stability of mHLA-DRd. RTR were re-assessed after an interval 243 of a median (IQR) of 238 (196 -250, n=116 ) and 385 (264 -434, n=91) days. Repeat mHLA-DRd 244 exhibited a stable moderate to strong correlation compared to enrolment values ( Figure 4 ) and did not 245 demonstrate a significant shift from baseline values over study follow-up (F(1.86, 189.1) = 0.43, 246 p=0.64). 11 participants had a reduction in the dose of one or more of their immunosuppressive 247 agents during the study follow-up period with mHLA-DRd quantified before and after; no significant 248 change between these two timepoints was seen (data not shown). 249

We next assessed correlation between mHLA-DRd and lymphocyte and monocyte populations. 252 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 23, 2022. ; https://doi.org/10. 1101 /2022 The total monocyte number in transplant recipients demonstrated no correlation with mHLA-DRd (r 253 -0.11, p 0.20). Similarly, no correlation was found with total lymphocyte count or with major T cell 254 subsets (r <0.2 for all populations studied, Supplementary Figure 3 ). Specifically, we previously 255 reported an increased risk of cutaneous malignancy in transplant recipients exhibiting evidence of T 256 cell immunosenescence (28) -no correlation was seen between mHLA-DRd and phenotypic markers 257 of this. In those not taking azathioprine, which has a marked effect upon B and NK cell populations 258 (28) Figure 4B ). However, mHLA-DRd correlated strongly with the accumulation of 267 CD19 -CD3 -CD56 -CD14 +/int CD11b + CD33 + HLA-DR lo myeloid-derived suppressor cell-like monocytes 268 (mMDSC-like), both in terms of calculated absolute number and proportion of the total monocyte 269 gate ( Figure 6B and 6C). Goodness-of-fit (r 2 ) testing suggested mMDSC-like cell accumulation 270 explained around 60-65% of mHLA-DRd variation at a univariate level. There was no difference 271 between monocyte populations when stratified by corticosteroid use (Supplementary Figure 4C) . 272

in the absence of major changes in circulatory cytokine concentration. 274

In order to assess what transcriptomic pathways might be driving the changes in mHLA-DRd across 275 the monocyte population, total RNA from enriched monocytes from RTR with high and low levels of 276 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 23, 2022. ; https://doi.org/10.1101/2022.03.23.22272699 doi: medRxiv preprint mHLA-DRd, matched for age and prednisolone use, was analysed using the nCounter 'Human 277

Myeloid Innate Immunity' panel. This panel includes 770 genes in 19 different pathways and 278 processes related to myeloid cell function. The details of participants included in this analysis are 279 given in Supplementary Table 3 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 23, 2022. ; https://doi.org/10.1101/2022.03.23.22272699 doi: medRxiv preprint each other, none demonstrated significant correlation with mHLA-DRd (Supplementary Figure 6) . 300

There was no difference in the serum concentration of any cytokine when stratified by prednisolone 301 use (data not shown). 302

Taken together, the above results suggest that decreased mHLA-DRd is associated with dampened 303 inflammatory signalling and reduced chemotactic potential within the circulating monocyte pool, in 304 the absence of a discernable change in serum cytokines and markers of systemic inflammation. Figure 7A ). Univariable analysis confirmed those with a mHLA-DRd below this cut-off were at 321 double the risk of subsequent malignancy during the following year ( Figure 7B and Table 3 ). This 322 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 23, 2022. ; https://doi.org/10.1101/2022.03.23.22272699 doi: medRxiv preprint propensity remained significant upon multivariable adjustment and upon correcting for the 323 competing risk of death or graft loss (Table 3) . 324

Discussion 325

Malignancy is a major contributor to patient morbidity and mortality, which remains relatively 326 unchanged over the last thirty years (9). Greater understanding of the mechanism which predispose to 327 cancer development are sorely needed, to facilitate studies into targeted intervention. Based on data 328 from short-term outcomes in lung and liver transplantation, with renewed interest in mHLA-DRd 329 driven by trials of cell therapy, we investigated the mechanisms and consequences of reduced 330 mHLA-DRd in long-term transplant outcomes. The use of a long-term population at high risk of 331 malignancy development, by virtue of their cumulative immunosuppressive burden or previous 332 keratinocyte malignancy, enriched our study population for the outcome of interest (namely cancer), 333 allowing easier study of contributory factors. 334

We found that mHLA-DRd is a distinct immunological parameter, demonstrating stability over a 335 twelve month period, that does not correlate with clinically utilised inflammatory markers, major 336 circulating cytokines, or circulating lymphocytes, but appears to reflect accumulation of 337 CD14 + CD11b + CD33 + HLA-DR lo cells within the monocyte compartment. Monocytic myeloid-338 derived suppressor cells (mMDSC) are a heterogenous population and a definitive marker is yet to be 339 depending on the context of the stimulus (36). It has been suggested that cells with a MDSC 345 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 23, 2022. ; https://doi.org/10.1101/2022.03.23.22272699 doi: medRxiv preprint phenotype but where suppressive function has not been demonstrated should be termed (monocytic) 346

When we investigated transcriptomic changes that underlie the reduction in mHLA-DRd, we did not 348 find any significantly differentially expressed genes after correction for multiple testing. There are 349 three possible explanations for this: the first is that this was an assessment of the whole monocyte 350 compartment and thus bulk RNA analysis may miss subtle changes within one subset (i.e. 351 accumulation of mMDS-LC, as evidenced by a lack of clustering of MDSC-related genes). Secondly, 352 the rapid upregulation of mHLA-DRd ex vivo when stored at room temperature (Supplementary 353 Figure S1 ) suggests that pathways that control mHLA-DRd in non-suppressive monocyte populations 354 may be regulated at the post-transcriptomic level. The use of gene set enrichment analysis allows for 355 interrogation and identification of pathways that may be involved in this process without assumption 356 about the magnitude of change or use of pre-defined limits. Interrogating the Gene Ontology 357 knowledgebase revealed that monocytes from RTR with low mHLA-DRd exhibited evidence of 358 dampened chemokine and cytokine signalling and chemotaxis. Our data may provide a second, more 359 subtle, mechanism by which reduced mHLA-DRd is associated with poorer outcomes in a number of 360 clinical scenarios, due to dampened responses to cytokine and chemotactic signals leading to altered 361 trafficking of monocytes to the periphery. The lack of correlation with circulating cytokines and CRP 362 suggests that the dampened responses are not due to a systemic reduction in inflammatory mediators. 363

The effect of corticosteroids upon mHLA-DRd was notable. The suppression of mHLA-DRd was 364 not due to accumulation of MDS-LC, as no major differences were seen in subpopulations. The 365 effect of prednisolone on mHLA-DRd is consistent with other reports but, in contrast to these, we did 366 not see a major difference in monocyte subpopulations (particularly CD14 hi CD16 -, where many 367 MDS-LC are found) (22, 37). It should be remarked that the majority of our cohort were on a 368 relatively small daily dose of prednisolone and this might explain the discrepancy in findings. It is 369 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 23, 2022. ; https://doi.org/10.1101/2022.03.23.22272699 doi: medRxiv preprint likely that corticosteroids dampen inflammatory response pathways, leading to decreased mHLA-370 DRd, independent of the effect upon monocyte populations or circulating markers of inflammation. 371

Given the association with accumulation of mMDS-LC and evidence of reduced inflammatory 372 response, we sought to assess whether reduced mHLA-DRd was associated with poorer medium-373 term outcomes; namely increased risk of subsequent malignancy, even though the vast majority of 374 RTR demonstrated mHLA-DRd within the previously cited 'normal' range (25) animal models (40); notably we did not observe a correlation between circulating Treg and reduced 381 mHLA-DRd, though this does not preclude peripheral expansion of Treg. Cutaneous SCC was the 382 most common cancer seen during follow-up and it is noteworthy that mMDSC are implicated both in 383 the mutagenesis and progression of cSCC. mMDSC are induced by some strains of beta-genus 384 human papillomavirus, the presence of which has been controversially linked to cutaneous SCC 385 development (38, 42, 43) . In mouse model of UV radiation and HPV oncogene-induced cSCC, 386

Ly6C hi monocytes infiltrate and accumulate at the site of UV radiation injury and are essential for 387 carcinogenesis (44); however in this model the mechanism appears to be through their pro-388 inflammatory effects. The Th2-polarised cytokine state seen within cutaneous SCC from transplant 389 recipients may lead to mMDSC induction and reduced circulating mHLA-DRd (38, 45). The 390 potential use of mHLA-DRd as a marker of mMDSC accumulation is appealing in that standard 391 curve generation and the simplicity of gating is likely to be more reproducible in multi-centre studies 392 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 23, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 and in clinical practice (25). How the changes in circulating monocyte phenotype relates to changes 393 in peripheral monocyte behaviour are a focus of ongoing study. 394

Whilst this study provides important insight into the clinical factors and mechanisms that drive 395 mHLA-DRd and the clinical sequelae of reductions in this, there were some limitations. Survivor 396 bias of long-term RTR at recruitment may diminish the apparent association between mHLA-DRd 397 and malignancy. Secondly, cutaneous squamous cell carcinoma was the main malignancy type in this 398 study, reflecting its frequency amongst long-term, Caucasian RTR (2). Whether reduced mHLA-DRd 399 predicts other malignancy in other ethnic populations or in other settings where immunosuppression 400 is used, such as autoimmunity, is unclear. Due to the exploratory nature of this study, no a priori 401 power calculation was performed and this leaves a possibility of a type I error; however our data 402 would be consistent with, though an extrapolation of, findings demonstrating an impaired immune 403 response with diminished mHLA-DRd in multiple other settings. Finally, only a small subset of our 404 cohort had a change in their immunosuppressive therapy during study follow-up, and these changes 405 were highly heterogeneous; therefore the extent to which mHLA-DRd is dynamic as a response to 406 changes in immunosuppression is unclear. 407

In conclusion, we report that reduced mHLA-DRd is a distinct immunological marker that reflects 408 the accumulation of mMDSC-like cells within the monocyte population and dampening of pathways 409 relating to inflammation, cytokine signalling and chemotaxis. This is clinically relevant in that it is 410 associated with the subsequent development of malignancy. Our findings will drive further study into 411 the mechanisms underlying this association with cancer development, which may reveal novel 412 avenues for therapeutic manipulation. 413

The authors declare that the research was conducted in the absence of any commercial or financial 415 relationships that could be construed as a potential conflict of interest. 416 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 23, 2022. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 23, 2022. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 23, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 23, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 23, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 23, 2022. ; https://doi.org/10.1101/2022.03.23.22272699 doi: medRxiv preprint of mMDSC-like cells within the monocyte population and (C) absolute number of mMDSC-like 608 cells. Spearman's test was used to assess goodness-of-fit (r 2 ) and significance. 609 Receiver-operator characteristic (ROC) curve for prediction of malignancy in the year following 616 mHLA-DRd quantification. Predictive performance is given (area under curve (AUC) and 95% 617 confidence interval) as well as the optimal cut-off and corresponding sensitivity and specificity. (B) 618

Kaplan-Meier curve demonstrating cumulative incidence of malignancy stratified by mHLA-DRd. 619 (unadjusted and adjusted hazard ratios and P values are given in Table 3 ; log-rank test for difference 620 between curves is provided in-plot). 621 622 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) and use of prednisolone at recruitment were used in the multivariate models. Two models were 638 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 23, 2022. ; https://doi.org/10.1101/2022.03.23.22272699 doi: medRxiv preprint generated: one using Cox Proportionate Hazards modelling and a second using competing-risk 639 modelling, using graft loss and death as competing risks. 640 641 642 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 23, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 

Death after Kidney 436 Transplantation: An Analysis by Era and Time Post-Transplant

Incidence of Skin 439 Cancer after Renal Transplantation in the Netherlands

A 442 Surveillance Model for Skin Cancer in Organ Transplant Recipients: A 22-Year Prospective Study in 443 an Ethnically Diverse Population

Cancer Mortality 446 in Kidney Transplant Recipients: An Australian and New Zealand Population-Based Cohort Study

Cancer Incidence before and after Kidney Transplantation

Survival after a Cancer 458 Diagnosis among Solid Organ Transplant Recipients in the United States

Arising in Organ Transplant Recipients Are Associated with Adverse Outcomes Compared with the 462

T Cell Allorecognition Pathways in 464 Solid Organ Transplantation

Hla-Dr Expression 467 on Monocytes Is Decreased in Polytraumatized Patients

Advances in the Understanding and Treatment of Sepsis-Induced 470

Immunosuppression

Human Leukocyte Antigen Dr Expression in Young Infants Undergoing Cardiopulmonary Bypass

Hla-Dr Expression on Monocytes and Systemic Inflammation in Patients with Ruptured 477 Abdominal Aortic Aneurysms

Expression for Prediction of Anastomotic Leak after Colorectal Surgery

Immunosuppressive Monocytes Predict Disease Severity in Patients with Acute Pancreatitis

Measurement by Flow Cytometry in Covid-19 Patients: An Interim Review

Long-Term Safety, and Immune Monitoring of Regulatory T Cell Therapy in Living Donor Kidney 489 Transplant Recipients

Regulatory T 492 Cells for Minimising Immune Suppression in Kidney Transplantation: Phase I/Iia Clinical Trial

Cell Therapy in Kidney Transplantation (the One Study): A Harmonised Design and Analysis of 496

Phase 1/2a Trials

Immunologic Monitoring of 499 T-Lymphocyte Subsets and Hla-Dr-Positive Monocytes in Kidney Transplant Recipients: A 500 Prospective

Low Hla-Dr Expression on Peripheral Blood Monocytes Predicts Bacterial Sepsis after Liver 504 Transplantation: Relation with Prednisolone Intake

Leukocyte Antigen-Dr Expression on Peripheral Blood Monocytes and the Risk of Pneumonia in 508

Pediatric Lung Transplant Recipients

Diagnostic Relevance of Procalcitonin, Il-511 6 and Cellular Immune Status in the Early Phase after Liver Transplantation

518 Strengthening the Reporting of Observational Studies in Epidemiology (Strobe) Statement: 519 Guidelines for Reporting Observational Studies

Cd8+ Immunosenescence Predicts Post-Transplant 524

Cutaneous Squamous Cell Carcinoma in High-Risk Patients

Human Monocyte Subsets by Whole Blood Flow Cytometry Analysis

Quantification Cycle (Cq) Data

Myeloid-Derived Suppressor Cells in the Era of 541 Increasing Myeloid Cell Diversity

Myeloid-Derived Suppressor 548 Cells in Solid Tumors

Mechanisms Govern Populations of Myeloid-Derived Suppressor Cells in Chronic Viral Infection 551 and Cancer

The Role of the Immune System in 556

Myeloid-Derived Suppressor Cells Accumulate in Renal Transplant Patients and Mediate Cd4(+)

Foxp3(+) Treg Expansion

Early Posttransplant Mobilization of Monocytic Myeloid-Derived 567

Suppressor Cell Correlates with Increase in Soluble Immunosuppressive Factors and Predicts Cancer 568 in Kidney Recipients

Human Papillomavirus and Posttransplantation Cutaneous Squamous Cell Carcinoma: A Multicenter

The authors would like to thank the staff and patients at the Oxford Transplant Unit for their support 426 of this study, in particular S. Ruse for assisting in coordinating the follow-up of participants. We are 427 grateful to G. Betts and R.